» Articles » PMID: 9778245

Negative Regulation of PKB/Akt-dependent Cell Survival by the Tumor Suppressor PTEN

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 1998 Oct 20
PMID 9778245
Citations 941
Authors
Affiliations
Soon will be listed here.
Abstract

PTEN is a tumor suppressor with sequence homology to protein tyrosine phosphatases and the cytoskeletal protein tensin. mPTEN-mutant mouse embryos display regions of increased proliferation. In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a number of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival. Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation. Furthermore, PTEN negatively regulates intracellular levels of phosphatidylinositol (3,4,5) trisphosphate in cells and dephosphorylates it in vitro. Our results show that PTEN may exert its role as a tumor suppressor by negatively regulating the PI3'K/PKB/Akt signaling pathway.

Citing Articles

Genetically encoded biosensor for fluorescence lifetime imaging of PTEN dynamics in the intact brain.

Kagan T, Gabay M, Meenakshisundaram A, Levi Y, Eid S, Malchenko N Nat Methods. 2025; .

PMID: 39979596 DOI: 10.1038/s41592-025-02610-9.


Breast Cancer with a Newly Diagnosed Variant in the Gene: A Case Report.

Maeda Y, Ikeda T, Sato A, Matsumoto A, Jinno H Surg Case Rep. 2025; 11(1).

PMID: 39974553 PMC: 11835985. DOI: 10.70352/scrj.cr.24-0082.


Advances in cancer genomics and precision oncology.

Heo Y, Kim W, Cho Y, Jung J, Kim N, Choi I Genes Genomics. 2025; .

PMID: 39849190 DOI: 10.1007/s13258-024-01614-7.


Traditional Chinese medicine in the treatment of -related gastritis: The mechanisms of signalling pathway regulations.

Zhang P, Li L, Qu H, Chen G, Xie M, Chen Y World J Gastroenterol. 2025; 31(3):96582.

PMID: 39839895 PMC: 11684169. DOI: 10.3748/wjg.v31.i3.96582.


Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8T and tumor cells.

Zhu G, Tang Z, Chu T, Wang B, Chen S, Tao C Signal Transduct Target Ther. 2025; 10(1):25.

PMID: 39837814 PMC: 11751439. DOI: 10.1038/s41392-024-02118-2.